Drug Profile
PF 4691502
Alternative Names: PF-04691502; PF-4691502Latest Information Update: 22 Jul 2020
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Solid tumours
Most Recent Events
- 22 Jul 2020 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 111th Annual Meeting of the American Association for Cancer Research - II(AACR-2020)
- 23 Jan 2014 Pfizer terminates a phase II trial in Endometrial cancer in USA, Australia, Canada, Germany, Japan, Poland, Russia, Slovakia, Spain and the United Kingdom (NCT01420081)
- 12 Nov 2012 Discontinued - Phase-II for Endometrial cancer in USA (PO)